Andreeff M. (Ed.) Targeted Therapy of Acute Myeloid Leukemia

Springer, 2015. — 826 p. — (Current Cancer Research). — ISBN: 978-1-4939-1392-3, 978-1-4939-1393-0.Presents updated contemporary classification systems of myeloid leukemias, their genetic defects and the proteomic alterations characteristic of acute myeloid leukemia
Summarizes and interprets targeted in acute myeloid therapies, along with future therapeutics
Serves as a useful guideline to scientists, translational researchers and clinicians in the fieldThis book provides an unprecedented overview of "Targeted Therapies" for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make "leukemia history" in the near future.Genetics and Classification of Acute Myeloid Leukemia
The Use of “Omics” to Guide the Selection of Targeted Therapy
Roles of Apoptosis-Regulating Bcl-2 Family Genes in AML
Bcl-2 Family: Translational Aspects
IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia
Targeting p53 Tumor Suppressor for AML Therapy
AML-Selective Apoptosis Induction by Rationally Designed Death Ligand Fusion Proteins
PIM Kinases in AML
Development of Midostaurin as a Tyrosine Kinase Inhibitor
FLT3 in AML
FLT3-ITD. Clinical (Sorafenib/AC220)
Nucleophosmin (NPM1)
Raf/MEK/ERK Signaling
The Role of Translational Medicine in Optimization of Therapies Targeting the RAS-MAP Kinase Pathway
Clinical Use of Farnesyltransferase Inhibitors
The PI3K-AKT-mTOR Signaling Network in AML
Targeting the PI3 Kinase-mTOR Signaling Pathway in AML
Aurora Kinases
The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid Leukemia
AML: Deacetylases
Methylation in AML: Clinical Applications
PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response
Arsenic Trioxide in Untreated APL
Targeting PML-RARα with Retinoids
NR4A Orphan Receptors as Drug Targets
Antibody-Based Therapeutics Targeting CD33, CD45, and CD66
New Heterogeneity of the Leukemic Stem Cells
Targeting Leukemia Stem Cells
Regulation of Hematopoiesis by CXCL12/CXCR4 Signaling
CXCR4/CXCL12 as a Therapeutic Target
VLA-4: A Cell’s Consequential Encounter
VLA-4 Function and Prognosis in Acute Myeloid Leukemia
VLA4 in Acute Lymphoblastic Leukemia
The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs
MicroRNAs as Therapeutic Targets
Clinical Implications of MicroRNAs in AML
Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid Leukemias
Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia Cells
NK-Cell Immunotherapy for AML
Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias
Indications for Hematopoietic Transplantation for AML
Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies
Erratum to: NK-Cell Immunotherapy for AML